Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Nov 6 - Nov 11
Both medications reduce blood sugar and A1c levels and help with weight loss, and both also contribute to heart health
2022;14(6):e26121
In these phase III studies the DPP-4 inhibitors were examined as monotherapy in drug-nave patients and as add-on to on-going therapy with metformin, sulfonylurea therapy, thiazolidinedione therapy and therapy with exogenous insulin in type 2 diabetes (Table 2)
Glycated hemoglobin levels decreased by 0.8 points
Louie SM, Grossman EA, Crawford LA, Ding L, Camarda R, Huffman TR, Miyamoto DK, Goga A, Weerapana E, Nomura DK (2016) GSTP1 is a driver of triple-negative breast cancer cell metabolism and pathogenicity
US$ 21.34
US$ 26.83
US$ 20.74
